Skip to main content

Towards evidence-based combinations of approved and novel cancer drugs

Searching for OpenAIRE data...


A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways

Author(s): D. Romaniello, L. Mazzeo, M. Mancini, I. Marrocco, A. Noronha, M. Kreitman, S. Srivastava, S. Ghosh, M. Lindzen, T.M. Salame, A. Onn, J. Barr, Y. Yarden
Published in: Clinical Cancer Research, Issue November 15, 2018, 2018, Page(s) 5610-5621, ISSN 1557-3265
DOI: 10.1158/1078-0432.ccr-18-0450

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Author(s): Maicol Mancini, Hilah Gal, Nadège Gaborit, Luigi Mazzeo, Donatella Romaniello, Tomer Meir Salame, Moshit Lindzen, Georg Mahlknecht, Yehoshua Enuka, Dominick GA Burton, Lee Roth, Ashish Noronha, Ilaria Marrocco, Dan Adreka, Raya Eilam Altstadter, Emilie Bousquet, Julian Downward, Antonio Maraver, Valery Krizhanovsky, Yosef Yarden
Published in: EMBO Molecular Medicine, Issue 10/2, 2018, Page(s) 294-308, ISSN 1757-4676
DOI: 10.15252/emmm.201708076

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Author(s): Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman, Jeanette Clarissa Kittel, Nadege Gaborit, Gretchen Bergado Baez, Belinda Sanchez, Raya Eilam, Eli Pikarsky, Luis Paz-Ares, Yosef Yarden
Published in: Cancers, Issue 12/9, 2020, Page(s) 2394, ISSN 2072-6694
DOI: 10.3390/cancers12092394